{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:37:45Z","timestamp":1791873465082,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006453","name":"Taisho Toyama Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jpet.2025.103624","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T18:54:53Z","timestamp":1749236093000},"page":"103624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Preclinical pharmacological profiles of vornorexant, a novel potent dual orexin receptor antagonist"],"prefix":"10.1016","volume":"392","author":[{"given":"Hirohiko","family":"Hikichi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Tokumaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuki","family":"Taruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7936-5890","authenticated-orcid":false,"given":"Yoshihiro","family":"Konno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Karasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Marumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teisuke","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2553-8195","authenticated-orcid":false,"given":"Takao","family":"Yoshimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Chaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6982-5444","authenticated-orcid":false,"given":"Noriko","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jpet.2025.103624_bib1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/sleep\/30.3.263","article-title":"The direct and indirect costs of untreated insomnia in adults in the United States","volume":"30","author":"Ozminkowski","year":"2007","journal-title":"Sleep"},{"issue":"9","key":"10.1016\/j.jpet.2025.103624_bib2","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.5665\/SLEEP.1230","article-title":"Insomnia and the performance of US workers: results from the America insomnia survey","volume":"34","author":"Kessler","year":"2011","journal-title":"Sleep"},{"issue":"11","key":"10.1016\/j.jpet.2025.103624_bib3","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1177\/0269881113503509","article-title":"Benzodiazepines: risks and benefits. A reconsideration","volume":"27","author":"Baldwin","year":"2013","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jpet.2025.103624_bib4","series-title":"Textbook of Addiction Treatment","first-page":"141","article-title":"Benzodiazepine and nonbenzodiazepine hypnotics (Z-drugs): the other epidemic","author":"Umbricht","year":"2020"},{"issue":"1","key":"10.1016\/j.jpet.2025.103624_bib5","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.jpet.2025.103624_bib6","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.jpet.2025.103624_bib7","doi-asserted-by":"crossref","first-page":"10911","DOI":"10.1073\/pnas.96.19.10911","article-title":"Orexin A activates locus coeruleus cell firing and increases arousal in the rat","volume":"96","author":"Hagan","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.jpet.2025.103624_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0306-4522(01)00512-7","article-title":"Orexins\/hypocretins excite basal forebrain cholinergic neurones","volume":"108","author":"Eggermann","year":"2001","journal-title":"Neuroscience"},{"issue":"21","key":"10.1016\/j.jpet.2025.103624_bib9","doi-asserted-by":"crossref","first-page":"9453","DOI":"10.1523\/JNEUROSCI.22-21-09453.2002","article-title":"Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions","volume":"22","author":"Liu","year":"2002","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/j.jpet.2025.103624_bib10","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1006\/bbrc.2001.6318","article-title":"Orexins activate histaminergic neurons via the orexin 2 receptor","volume":"290","author":"Yamanaka","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.jpet.2025.103624_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.brainres.2005.08.016","article-title":"Retrograde study of hypocretin-1 (orexin-A) projections to subdivisions of the dorsal raphe nucleus in the rat","volume":"1059","author":"Lee","year":"2005","journal-title":"Brain Res"},{"issue":"2","key":"10.1016\/j.jpet.2025.103624_bib12","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/bph.12415","article-title":"The hypocretins\/orexins: integrators of multiple physiological functions","volume":"171","author":"Li","year":"2014","journal-title":"Br J Pharmacol"},{"issue":"17","key":"10.1016\/j.jpet.2025.103624_bib13","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1523\/JNEUROSCI.6506-10.2011","article-title":"Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep","volume":"31","author":"Mieda","year":"2011","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/j.jpet.2025.103624_bib14","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/npp.2010.224","article-title":"Differential effects of the dual orexin receptor antagonist almorexant and the GABAA-\u03b11 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat","volume":"36","author":"Steiner","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.jpet.2025.103624_bib15","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/jpet.115.225466","article-title":"Characterization of JNJ-42847922, a selective orexin-2 receptor antagonist, as a clinical candidate for the treatment of insomnia","volume":"354","author":"Bonaventure","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"10.1016\/j.jpet.2025.103624_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039131","article-title":"Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone","volume":"7","author":"Morairty","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jpet.2025.103624_bib17","doi-asserted-by":"crossref","first-page":"765","DOI":"10.5664\/jcsm.8294","article-title":"Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening","volume":"16","author":"Murphy","year":"2020","journal-title":"J Clin Sleep Med"},{"issue":"6","key":"10.1016\/j.jpet.2025.103624_bib18","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/cpt.2592","article-title":"Driving performance after bedtime administration of daridorexant, assessed in a sensitive simulator","volume":"111","author":"Muehlan","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"10.1016\/j.jpet.2025.103624_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115489","article-title":"Discovery of ORN0829, a potent dual orexin 1\/2 receptor antagonist for the treatment of insomnia","volume":"28","author":"Futamura","year":"2020","journal-title":"Bioorg Med Chem"},{"issue":"5","key":"10.1016\/j.jpet.2025.103624_bib20","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/bcpt.13930","article-title":"Pharmacokinetics, pharmacodynamics and safety profile of the dual orexin receptor antagonist vornorexant\/TS-142 in healthy Japanese participants following single\/multiple dosing: randomized, double-blind, placebo-controlled phase-1 studies","volume":"133","author":"Kambe","year":"2023","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"7","key":"10.1016\/j.jpet.2025.103624_bib21","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1007\/s00213-022-06089-6","article-title":"Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study","volume":"239","author":"Uchiyama","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jpet.2025.103624_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2021.105053","article-title":"Nonclinical evaluation of abuse liability of the dual orexin receptor antagonist lemborexant","volume":"127","author":"Asakura","year":"2021","journal-title":"Regul Toxicol Pharmacol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103624_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsz076","article-title":"Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep\/wake regulation","volume":"42","author":"Beuckmann","year":"2019","journal-title":"Sleep"},{"issue":"10","key":"10.1016\/j.jpet.2025.103624_bib24","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s00213-021-05954-0","article-title":"Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia","volume":"238","author":"Roch","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"issue":"1-2","key":"10.1016\/j.jpet.2025.103624_bib25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/01677063.2011.566953","article-title":"Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist","volume":"25","author":"Winrow","year":"2011","journal-title":"J Neurogenet"},{"issue":"6","key":"10.1016\/j.jpet.2025.103624_bib26","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.bmc.2015.01.044","article-title":"Discovery and in vitro and in vivo profiles of N-ethyl-N-[2-[3-(5-fluoro-2-pyridinyl)-1H-pyrazol-1-yl]ethyl]-2-(2H-1,2,3-triazol-2-yl)-benzamide as a novel class of dual orexin receptor antagonist","volume":"23","author":"Suzuki","year":"2015","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"10.1016\/j.jpet.2025.103624_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0026-895X(25)15016-5","article-title":"The kinetics of competitive radioligand binding predicted by the law of mass action","volume":"25","author":"Motulsky","year":"1984","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103624_bib28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1124\/jpet.109.152009","article-title":"Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat","volume":"330","author":"Dugovic","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103624_bib29","series-title":"The rat brain in stereotaxic coordinates","author":"Paxinos","year":"1998"},{"key":"10.1016\/j.jpet.2025.103624_bib30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-2202-14-90","article-title":"The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold","volume":"14","author":"Gotter","year":"2013","journal-title":"BMC Neurosci"},{"issue":"2","key":"10.1016\/j.jpet.2025.103624_bib31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.117.241422","article-title":"In vitro and in silico characterization of lemborexant (E2006), a novel dual orexin receptor antagonist","volume":"362","author":"Beuckmann","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.jpet.2025.103624_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1183","article-title":"Preclinical metabolism and the disposition of vornorexant\/TS-142, a novel dual orexin 1\/2 receptor antagonist for the treatment of insomnia","volume":"12","author":"Konno","year":"2024","journal-title":"Pharmacol Res Perspect"},{"issue":"3","key":"10.1016\/j.jpet.2025.103624_bib33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1124\/jpet.117.241596","article-title":"The use of physiology-based pharmacokinetic and pharmacodynamic modeling in the discovery of the dual orexin receptor antagonist ACT-541468","volume":"362","author":"Treiber","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103624_bib34","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-pharmtox-010716-104837","article-title":"The discovery of suvorexant, the first orexin receptor drug for insomnia","volume":"57","author":"Coleman","year":"2017","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103624_bib35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00002826-199704000-00002","article-title":"Minimal rebound insomnia after treatment with 10-mg zolpidem","volume":"20","author":"Ware","year":"1997","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103624_bib36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pbb.2008.01.021","article-title":"Gaboxadol -- a different hypnotic profile with no tolerance to sleep EEG and sedative effects after repeated daily dosing","volume":"90","author":"Ebert","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"10.1016\/j.jpet.2025.103624_bib37","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials","volume":"79","author":"Herring","year":"2016","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.jpet.2025.103624_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2868","article-title":"Efficacy and safety of lemborexant as an alternative drug for patients with insomnia taking gamma-aminobutyric acid-benzodiazepine receptor agonists or suvorexant","volume":"38","author":"Okino","year":"2023","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.jpet.2025.103624_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1168100","article-title":"Treatment strategy for insomnia disorder: Japanese expert consensus","volume":"14","author":"Takaesu","year":"2023","journal-title":"Front Psychiatry"},{"issue":"2","key":"10.1016\/j.jpet.2025.103624_bib40","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.amjopharm.2006.06.006","article-title":"Management of chronic insomnia in elderly persons","volume":"4","author":"Bain","year":"2006","journal-title":"Am J Geriatr Pharmacother"},{"issue":"4","key":"10.1016\/j.jpet.2025.103624_bib41","first-page":"224","article-title":"Risks associated with long-term benzodiazepine use","volume":"88","author":"Johnson","year":"2013","journal-title":"Am Fam Physician"},{"issue":"4","key":"10.1016\/j.jpet.2025.103624_bib42","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40268-017-0207-7","article-title":"Benzodiazepines and Z-drugs: an updated review of major adverse outcomes reported on in epidemiologic research","volume":"17","author":"Brandt","year":"2017","journal-title":"Drugs R D"},{"issue":"4","key":"10.1016\/j.jpet.2025.103624_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0284726","article-title":"Effectiveness of suvorexant versus benzodiazepine receptor agonist sleep drugs in reducing the risk of hip fracture: findings from a regional population-based cohort study","volume":"18","author":"Yoshioka","year":"2023","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jpet.2025.103624_bib44","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/cmdc.201300003","article-title":"Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist","volume":"8","author":"Steiner","year":"2013","journal-title":"ChemMedChem"},{"issue":"6","key":"10.1016\/j.jpet.2025.103624_bib45","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00228-023-03485-5","article-title":"Association between nocturnal falls and hypnotic drug use in older patients at acute care hospitals","volume":"79","author":"Oda","year":"2023","journal-title":"Eur J Clin Pharmacol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652539837X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652539837X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T10:13:50Z","timestamp":1753870430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652539837X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S002235652539837X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103624","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical pharmacological profiles of vornorexant, a novel potent dual orexin receptor antagonist","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103624","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"103624"}}